KPTI
Price:
$0.7302
Market Cap:
$91.04M
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or ...[Read more]
Industry
Biotechnology
IPO Date
2013-11-06
Stock Exchange
NASDAQ
Ticker
KPTI
According to Karyopharm Therapeutics Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 3.62. This represents a change of 3.38% compared to the average of 3.50 of the last 4 quarters.
The mean historical Current Ratio of Karyopharm Therapeutics Inc. over the last ten years is 103.94. The current 3.62 Current Ratio has changed 248.22% with respect to the historical average. Over the past ten years (40 quarters), KPTI's Current Ratio was at its highest in in the December 2020 quarter at 974.88. The Current Ratio was at its lowest in in the March 2018 quarter at 2.85.
Average
103.94
Median
6.52
Minimum
3.00
Maximum
974.88
Discovering the peaks and valleys of Karyopharm Therapeutics Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 16.41%
Maximum Annual Current Ratio = 974.88
Minimum Annual Increase = -99.64%
Minimum Annual Current Ratio = 3.00
Year | Current Ratio | Change |
---|---|---|
2023 | 3.37 | -32.09% |
2022 | 4.96 | 41.60% |
2021 | 3.50 | -99.64% |
2020 | 974.88 | 16.41% |
2019 | 5.90 | -17.24% |
2018 | 7.13 | 137.76% |
2017 | 3.00 | -62.45% |
2016 | 7.99 | -31.93% |
2015 | 11.74 | -30.51% |
2014 | 16.89 | -68.91% |
The current Current Ratio of Karyopharm Therapeutics Inc. (KPTI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
3.94
5-year avg
198.52
10-year avg
103.94
Karyopharm Therapeutics Inc.’s Current Ratio is less than X4 Pharmaceuticals, Inc. (6.07), less than HOOKIPA Pharma Inc. (3.86), less than Mereo BioPharma Group plc (6.07), less than Galera Therapeutics, Inc. (5.63), less than Acumen Pharmaceuticals, Inc. (17.37), greater than CytomX Therapeutics, Inc. (1.00), less than Nuvation Bio Inc. (11.49), less than Neoleukin Therapeutics, Inc. (15.33), greater than Assembly Biosciences, Inc. (2.74), greater than Lyra Therapeutics, Inc. (3.60), less than Replimune Group, Inc. (13.46), greater than Nuvectis Pharma, Inc. (3.17), less than Kronos Bio, Inc. (8.49), less than Gossamer Bio, Inc. (8.21), less than Agios Pharmaceuticals, Inc. (10.09), greater than bluebird bio, Inc. (1.55), less than Intercept Pharmaceuticals, Inc. (4.22), less than PMV Pharmaceuticals, Inc. (0), less than Rallybio Corporation (19.22), less than Generation Bio Co. (7.52), less than Mersana Therapeutics, Inc. (7.42), greater than Monte Rosa Therapeutics, Inc. (2.72), less than null (6.56),
Company | Current Ratio | Market cap |
---|---|---|
6.07 | $109.78M | |
3.86 | $159.50M | |
6.07 | $664.26M | |
5.63 | $4.08M | |
17.37 | $133.38M | |
1.00 | $93.74M | |
11.49 | $692.60M | |
15.33 | $8.20M | |
2.74 | $107.81M | |
3.60 | $17.85M | |
13.46 | $708.49M | |
3.17 | $115.27M | |
8.49 | $59.36M | |
8.21 | $205.87M | |
10.09 | $2.46B | |
1.55 | $101.94M | |
4.22 | $794.69M | |
0 | $77.28M | |
19.22 | $45.64M | |
7.52 | $145.50M | |
7.42 | $165.61M | |
2.72 | $349.21M | |
6.56 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Karyopharm Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Karyopharm Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Karyopharm Therapeutics Inc.'s Current Ratio?
How is the Current Ratio calculated for Karyopharm Therapeutics Inc. (KPTI)?
What is the highest Current Ratio for Karyopharm Therapeutics Inc. (KPTI)?
What is the 3-year average Current Ratio for Karyopharm Therapeutics Inc. (KPTI)?
What is the 5-year average Current Ratio for Karyopharm Therapeutics Inc. (KPTI)?
How does the current Current Ratio for Karyopharm Therapeutics Inc. (KPTI) compare to its historical average?